Your browser doesn't support javascript.
loading
Genetic heterogeneity in Cornelia de Lange syndrome (CdLS) and CdLS-like phenotypes with observed and predicted levels of mosaicism.
Ansari, Morad; Poke, Gemma; Ferry, Quentin; Williamson, Kathleen; Aldridge, Roland; Meynert, Alison M; Bengani, Hemant; Chan, Cheng Yee; Kayserili, Hülya; Avci, Sahin; Hennekam, Raoul C M; Lampe, Anne K; Redeker, Egbert; Homfray, Tessa; Ross, Alison; Falkenberg Smeland, Marie; Mansour, Sahar; Parker, Michael J; Cook, Jacqueline A; Splitt, Miranda; Fisher, Richard B; Fryer, Alan; Magee, Alex C; Wilkie, Andrew; Barnicoat, Angela; Brady, Angela F; Cooper, Nicola S; Mercer, Catherine; Deshpande, Charu; Bennett, Christopher P; Pilz, Daniela T; Ruddy, Deborah; Cilliers, Deirdre; Johnson, Diana S; Josifova, Dragana; Rosser, Elisabeth; Thompson, Elizabeth M; Wakeling, Emma; Kinning, Esther; Stewart, Fiona; Flinter, Frances; Girisha, Katta M; Cox, Helen; Firth, Helen V; Kingston, Helen; Wee, Jamie S; Hurst, Jane A; Clayton-Smith, Jill; Tolmie, John; Vogt, Julie.
Afiliação
  • Ansari M; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Poke G; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Ferry Q; Visual Geometry Group, Department of Engineering Science, University of Oxford, Oxford, UK Medical Research Council Functional Genomics Unit, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.
  • Williamson K; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Aldridge R; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Meynert AM; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Bengani H; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Chan CY; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Kayserili H; Medical Genetics Department, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
  • Avci S; Medical Genetics Department, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
  • Hennekam RC; Department of Clinical Genetics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Lampe AK; South East of Scotland Clinical Genetic Service, Molecular Medicine Centre, Western General Hospital, Edinburgh, UK.
  • Redeker E; Department of Clinical Genetics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Homfray T; Medical Genetics Unit, St George's University of London, London, UK.
  • Ross A; North of Scotland Regional Genetics Service, Clinical Genetics Centre, Aberdeen, UK.
  • Falkenberg Smeland M; Department of Medical Genetics, University Hospital of Northern Norway, Tromsø, Norway.
  • Mansour S; Medical Genetics Unit, St George's University of London, London, UK.
  • Parker MJ; Sheffield Children's Hospital, NHS Foundation Trust, Sheffield, UK.
  • Cook JA; Sheffield Children's Hospital, NHS Foundation Trust, Sheffield, UK.
  • Splitt M; Northern Genetics Service, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK.
  • Fisher RB; Northern Genetics Service, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK.
  • Fryer A; Department of Clinical Genetics, Alder Hay Children's Hospital, Liverpool, UK.
  • Magee AC; Northern Ireland Regional Genetics Service (NIRGS), Belfast City Hospital, Belfast, UK.
  • Wilkie A; Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.
  • Barnicoat A; Clinical Genetics Department, Great Ormond Street Hospital, London, UK.
  • Brady AF; North West Thames Regional Genetics Service, Kennedy-Galton Centre, North West London Hospitals NHS Trust, Harrow, UK.
  • Cooper NS; West Midlands Regional Clinical Genetics Service, Birmingham Women's Hospital, West Midlands, UK.
  • Mercer C; Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.
  • Deshpande C; Department of Genetics, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Bennett CP; Clinical Genetics, Yorkshire Regional Genetics Service, Leeds, UK.
  • Pilz DT; Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK.
  • Ruddy D; Department of Genetics, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Cilliers D; Department of Clinical Genetics, The Churchill Hospital Old Road, Oxford, UK.
  • Johnson DS; Sheffield Children's Hospital, NHS Foundation Trust, Sheffield, UK.
  • Josifova D; Department of Genetics, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Rosser E; Clinical Genetics Department, Great Ormond Street Hospital, London, UK.
  • Thompson EM; SA Clinical Genetics Service, Women's & Children's Hospital, Adelaide, Australia Department of Paediatrics, University of Adelaide, Adelaide, Australia.
  • Wakeling E; North West Thames Regional Genetics Service, Kennedy-Galton Centre, North West London Hospitals NHS Trust, Harrow, UK.
  • Kinning E; West of Scotland Regional Genetics Service, Ferguson-Smith Centre for Clinical Genetics, Yorkhill Hospital, Glasgow, UK.
  • Stewart F; Northern Ireland Regional Genetics Service (NIRGS), Belfast City Hospital, Belfast, UK.
  • Flinter F; Department of Genetics, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Girisha KM; Department of Medical Genetics, Kasturba Medical College, Manipal University, Manipal, India.
  • Cox H; West Midlands Regional Clinical Genetics Service, Birmingham Women's Hospital, West Midlands, UK.
  • Firth HV; Department of Medical Genetics, Cambridge University Addenbrooke's Hospital, Cambridge, UK.
  • Kingston H; Faculty of Medical and Human Sciences, Manchester Centre for Genomic Medicine, Institute of Human Development, University of Manchester, Manchester Academic Health Science Centre (MAHSC), Manchester, UK.
  • Wee JS; Department of Dermatology, Kingston Hospital NHS Trust, Surrey, UK.
  • Hurst JA; Clinical Genetics Department, Great Ormond Street Hospital, London, UK.
  • Clayton-Smith J; Faculty of Medical and Human Sciences, Manchester Centre for Genomic Medicine, Institute of Human Development, University of Manchester, Manchester Academic Health Science Centre (MAHSC), Manchester, UK.
  • Tolmie J; West of Scotland Regional Genetics Service, Ferguson-Smith Centre for Clinical Genetics, Yorkhill Hospital, Glasgow, UK.
  • Vogt J; West Midlands Regional Clinical Genetics Service, Birmingham Women's Hospital, West Midlands, UK.
J Med Genet ; 51(10): 659-68, 2014 Oct.
Article em En | MEDLINE | ID: mdl-25125236
ABSTRACT

BACKGROUND:

Cornelia de Lange syndrome (CdLS) is a multisystem disorder with distinctive facial appearance, intellectual disability and growth failure as prominent features. Most individuals with typical CdLS have de novo heterozygous loss-of-function mutations in NIPBL with mosaic individuals representing a significant proportion. Mutations in other cohesin components, SMC1A, SMC3, HDAC8 and RAD21 cause less typical CdLS.

METHODS:

We screened 163 affected individuals for coding region mutations in the known genes, 90 for genomic rearrangements, 19 for deep intronic variants in NIPBL and 5 had whole-exome sequencing.

RESULTS:

Pathogenic mutations [including mosaic changes] were identified in NIPBL 46 [3] (28.2%); SMC1A 5 [1] (3.1%); SMC3 5 [1] (3.1%); HDAC8 6 [0] (3.6%) and RAD21 1 [0] (0.6%). One individual had a de novo 1.3 Mb deletion of 1p36.3. Another had a 520 kb duplication of 12q13.13 encompassing ESPL1, encoding separase, an enzyme that cleaves the cohesin ring. Three de novo mutations were identified in ANKRD11 demonstrating a phenotypic overlap with KBG syndrome. To estimate the number of undetected mosaic cases we used recursive partitioning to identify discriminating features in the NIPBL-positive subgroup. Filtering of the mutation-negative group on these features classified at least 18% as 'NIPBL-like'. A computer composition of the average face of this NIPBL-like subgroup was also more typical in appearance than that of all others in the mutation-negative group supporting the existence of undetected mosaic cases.

CONCLUSIONS:

Future diagnostic testing in 'mutation-negative' CdLS thus merits deeper sequencing of multiple DNA samples derived from different tissues.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Heterogeneidade Genética / Síndrome de Cornélia de Lange / Mosaicismo Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Heterogeneidade Genética / Síndrome de Cornélia de Lange / Mosaicismo Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article